Acticor Biotech
Thirty two years-experience in drug development (Pfizer, International Medical Director). Previous Board Director and Advisory Board Member of Ogeda (acquired by Astellas in 2017), actual Board Member of Chromacure SA, DIM3 and Ncardia. Presently serves as Chief Scientist and Regulatory as well as Senior Partner in Newton Biocapital Partners with office locations in Brussels and Tokyo.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Acticor Biotech
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.